Molluscum Contagiosum Treatment & Management

  • Author: Ashish C Bhatia, MD, FAAD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jan 5, 2012
 

Approach Considerations

In healthy patients, molluscum contagiosum is generally self-limited and heals spontaneously after several months. Individual lesions are seldom present for more than 2 months. Although treatment is not required, it may help to reduce autoinoculation or transmission to close contacts and improve clinical appearance.

Intervention may also be indicated if lesions persist. Therapeutic modalities include topical application of various medications, radiation therapy, and/or surgery. Each technique may result in scarring or postinflammatory pigmentary changes. Frequently, multiple treatment sessions are necessary because of the recurrence of treated lesions and/or the appearance of new lesions by autoinoculation. The benefit of therapy must exceed the risk.

Therapeutic options for molluscum contagiosum can be divided into broad categories, including the following:

  • Benign neglect
  • Direct lesional trauma
  • Antiviral therapy
  • Immune response stimulation

Choice of therapy

The most appropriate therapeutic approach largely depends on the clinical situation. In healthy children, a major goal is to limit discomfort, and benign neglect or minor, direct lesional trauma is appropriate. In adults who are more motivated to have their lesions treated, cryotherapy or curettage of individual lesions is effective and well tolerated.

In immunocompromised individuals, molluscum contagiosum may be very extensive and difficult to treat. The goal may be to treat the most troublesome lesions only. In severe cases, these patients may warrant more aggressive therapy with lasers, imiquimod, antiviral therapy, or a combination of these. Of course, effective antiretroviral therapy in patients with AIDS makes therapy of molluscum contagiosum much more effective.

The US Food and Drug Administration (FDA) has approved none of the topical or intralesional agents for treatment of molluscum contagiosum.

In a study of the treatment of molluscum contagiosum in children, Hanna et al determined that curettage was the most efficacious therapy. The investigators conducted a prospective, randomized trial that compared the efficacy and adverse effects of 4 recognized treatments of molluscum contagiosum in 124 children.[25] One group was treated with curettage, a second with cantharidin, a third with a combination of salicylic acid and lactic acid, and a fourth with imiquimod.

Curettage was found to be the most efficacious treatment and had the lowest rate of side effects. However, it must be performed with adequate anesthesia and is a time-consuming procedure. Cantharidin had moderate complications due to blisters and was slightly less effective. The topical keratolytic used was too irritating for children. Topical imiquimod was more effective than cantharidin but is expensive, and an optimum treatment schedule has yet to be reported.

Follow-up

Repeat examination is recommended 2-4 weeks after treatment. Retreatment often is necessary. Consider combination therapy in patients whose lesions respond poorly.

Activity

Instruct the patient to avoid activities or sports involving physical contact between infected areas of skin and exposed skin of other participants.

Deterrence and prevention

Most cases in adolescents and adults are secondary to sexual contact. Abstinence and careful selection of sexual partners are important. Whether condoms are effective in preventing spread is unclear. Good personal hygiene is important in limiting transmission. Autoinoculation may result from trauma, such as shaving or the manipulation of lesions by the patient.

Next

Pharmacologic Therapy

Clinical success has been reported with the use of the following topical agents, which may act as irritants, stimulating an immunologic response:

  • Imiquimod cream - An immune response modifier approved for the treatment of external genital and perianal warts in adults, imiquimod cream has been reported to be effective in the treatment of molluscum contagiosum[26, 27] ; imiquimod cream may be used in conjunction with cantharidin[28]
  • Cantharidin - Several studies report that cantharidin, a chemovesicant that can be used in combination with imiquimod, is effective in treating molluscum contagiosum; to test the patient's response to therapy, treat only a few lesions on the initial visit[28]
  • Tretinoin - This agent has reportedly been successful in the treatment of small molluscum contagiosum lesions
  • Bichloracetic acid
  • Trichloroacetic acid
  • Salicylic acid
  • Lactic acid
  • Glycolic acid
  • Silver nitrate

Tretinoin, cantharidin, and imiquimod may be dispensed to the patient with application instructions and close follow-up, although some recommend application in the office. Bichloracetic acid, trichloroacetic acid, salicylic acid, lactic acid, glycolic acid, and silver nitrate must be applied in the office by the physician.

Topical podophyllotoxin 0.5% cream self-administered twice daily for 3 weeks has been reported effective in a placebo-controlled, double-blind study.[29]

Reports have suggested that subcutaneous interferon alfa administered intralesionally may be useful in immunocompromised children.

A case report noted the efficacy of topical cidofovir in the treatment of disseminated molluscum in immunodepressed patients.[6] Cidofovir diphosphate was reported to inhibit molluscum contagiosum virus DNA polymerase activity.[30]

Previous
Next

Benign Neglect

Leaving mollusca to spontaneously resolve is often reasonable,[31] especially in young children for whom freezing or curettage may be painful and frightening. The dictum primum non nocere (first do no harm) has a special significance in children with minor, self-limited conditions. Many physicians refuse to treat children with small numbers of mollusca.

Lesions on the eyelids and central face may be particularly distressing to parents and patients. When possible, treat lesions at other locations first, with the hope that the treatment may stimulate the facial lesions to spontaneously resolve. When facial lesions require treatment, the best option is to treat them frequently with minor physical trauma. (See the image below.)

Lesions on the upper eyelid of a 3-year-old child.Lesions on the upper eyelid of a 3-year-old child.

More aggressive therapy may be required in patients in whom the extent of disease is intolerable and in patients who are immunocompromised.

Previous
Next

Direct Lesional Trauma

Takematsu et al reported that disruption of the epidermal wall of Henderson-Paterson bodies induces acute inflammatory changes by activation of the alternative complement pathway on exposure to the tissue fluids; furthermore, the Henderson-Paterson bodies release proinflammatory cytokines and other neutrophil chemotactic factors upon decomposition.[32] This supports the observation that minor trauma to molluscum lesions frequently produces an inflammatory response and resolution of the lesion. The Henderson-Paterson bodies can be ruptured and a local inflammatory response created by various forms of physical trauma and caustic topical agents.

Various caustic agents have been shown to be effective in treating molluscum contagiosum. Tretinoin, salicylic acid, and potassium hydroxide[33, 34] may be used. Cantharidin,[28, 35] silver nitrate,[36] trichloroacetic acid, and phenol also are options. Children may tolerate therapy with these agents better than curettage or cryotherapy. None of these caustic agents has been approved by the FDA for treatment of molluscum contagiosum.

Tretinoin cream

Tretinoin cream 0.1% or gel 0.025% is applied daily. Apply it to a region of skin with scattered lesions. It may produce eczema and may increase the number of lesions through autoinoculation; however, a small amount of tretinoin may be applied to individual lesions with the rough end of a broken toothpick. Rotate the toothpick, gently abrading the lesion and increasing the inflammatory response produced by the tretinoin. Treat lesions every few days until significant inflammation or resolution occurs.

Potassium hydroxide

Potassium hydroxide is a strong alkali that has long been known to digest proteins, lipids, and most other epithelial debris of skin scrapings to identify fungal infections. Topical 10% potassium hydroxide aqueous solution applied twice daily on each molluscum contagiosum lesion until all lesions undergo inflammation and superficial ulceration may be effective in clearing molluscum contagiosum in children.

Cantharidin

Cantharidin is a chemovesicant that is highly effective in treating molluscum contagiosum; however, this agent has lost favor with some physicians because of concerns regarding its safety. However, if cantharidin is used properly, it is very effective, safe, and well tolerated by children.

In a study by Silverberg et al in which 300 patients were treated with cantharidin, 90% of patients experienced complete clearing after an average of 2.1 visits. Blisters occurred at sites of application in 92% of patients. Temporary burning, pain, erythema, or pruritus was reported in 6-37% of patients. No major adverse effects were reported, and no patients experienced secondary bacterial infection. A total of 95% of parents reported that they would proceed with cantharidin therapy again.[37]

Cantharidin is not approved by the FDA for treatment of any condition; however, it has been used safely and effectively by dermatologists for many years.[38, 39] It is listed as acceptable therapy in the American Academy of Dermatology treatment guidelines for warts; however, because it has never been approved by the FDA for use in humans, it is no longer marketed as medical therapy in the United States. Cantharidin crystals and diluent can be purchased in the United States, and many dermatologists continue to use it. Cantharidin solution for the treatment of warts and molluscum is available in Canada and many other countries.

Salicylic acid

Seventeen percent salicylic acid in collodion (Compound W, Freezone, Wart-Off, Occlusal) is commonly used in treating verruca vulgaris. In most patients, repeated application to individual molluscum contagiosum lesions until an inflammatory response is generated is effective therapy.

Physical trauma

Varying degrees of physical trauma to individual lesions are used and are frequently quite successful. Physical trauma to individual molluscum contagiosum lesions can be performed with cryotherapy, lasers, curettage,[40, 41] expression of the central core with tweezers, rupture of the central core with a needle or a toothpick,[42, 43] electrodesiccation, shave removal, or duct tape occlusion.[44]

Instruct the parents to tease out the firm, white core at the center of lesions using a clean needle or a toothpick. The process of irritating the lesion usually causes it to inflame and resolve within 1-2 weeks. This safe and easy approach can be performed by the patient's parent, limiting the need for follow-up visits.

In an office setting, curettage of individual lesions is easy and very effective. With a sharp curette and a quick firm motion, small, individual lesions can be removed completely, with little or no bleeding. With practice and a sharp curette, the provider may perform this procedure with little or no discomfort. Older children, adolescents, and adults usually tolerate this procedure better.

Other simple mechanical methods, such as expression of the contents in the papule by squeezing it with forceps held parallel to the skin surface or shaving off the lesions with a sharp scalpel, are effective.

Lesions may also be treated with light electrodesiccation. At very low voltage settings, anesthesia may not be required.

Cryotherapy is the first-line treatment for many physicians, particularly in adolescents and adults. A brief freeze, which causes icing of the lesion and a thin rim of surrounding skin, is usually adequate. Treatment is repeated at intervals of 2-3 weeks until all lesions resolve. Achieve accurate spray of liquid nitrogen by using a disposable ear speculum. The small end is placed against the skin, and liquid nitrogen is sprayed into the funnel created. Lesions also may be treated with cotton-tip applicators chilled in liquid nitrogen and held against the lesion until a small amount of frosting occurs. Cryotherapy is painful and the smoke that rises off the cold applicator or the noise of the liquid nitrogen sprayer may be quite frightening to younger children.

Pulsed dye laser (PDL) therapy has been shown to be more than 95% successful in treating individual lesions with 1 treatment. PDL treatment of molluscum contagiosum has been used successfully in patients with AIDS. A significant reduction in the number of molluscum contagiosum lesions following a single treatment with the PDL can be attained. Treated areas may remain disease-free for months. Although cost and availability are major limiting factors for routine use, PDL therapy may be considered for treatment of extensive or resistant lesions. It may also be valuable in immunocompromised individuals with extensive disease.[45, 46, 47, 48, 49]

Treatment of molluscum contagiosum in patients with AIDS remains a challenge. The combination of 2 or more therapeutic modalities, such as carbon dioxide laser, PDL, and trichloroacetic acid, can be of much help to improve the quality of life of these patients.

The discomfort of curettage or other mechanical removal may be reduced. Lesions may be sprayed with ethyl chloride until frosting has occurred and then scraped away with a curette. The application of local anesthetic cream, EMLA (a eutectic mixture of 5% lignocaine and prilocaine) or its equivalent, may permit painless treatment. The cream is best applied under occlusion 1-2 hours before the planned procedure.

Previous
Next

Immune Response Stimulation

Imiquimod cream, intralesional interferon alfa,[50] and topical injections of streptococcal antigen[51] have been shown to be effective in treating patients with resistant molluscum contagiosum. The high cost of these products limits their use to more extensive or resistant infections. Imiquimod cream applied 3 times per week for 16 weeks is an option in severe cases. The dosing schedule and length of treatment require further evaluation.[25, 27, 52, 53, 54, 55, 56, 57]

Imiquimod is a novel topical immune response modifier that is a potent inducer of interferons. Various treatment regimens have been effective in treating molluscum contagiosum. In children[58, 59] and in some patients with AIDS-associated molluscum contagiosum,[60, 26] 1% cream applied 3 times daily or 5% cream applied at every bedtime for 4 weeks appears to be effective treatment.

A newer compound, Veregen,is a sinecatechin. Its true mechanism of action is unknown. It is a botanical extract from green tea. The 15% ointment is applied topically 3 times a day. It is FDA approved for topical therapy for external genital warts and perianal warts, but it is used off label for molluscum as well as verruca plana.[61]

Previous
Next

Antiviral Therapy

In immunocompromised patients, improvement of lesions has been observed in individual patients treated with ritonavir, cidofovir (intravenous and topical),[62, 63] and zidovudine. Not surprisingly, patients with AIDS and severe molluscum contagiosum improve with effective antiretroviral therapy.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Ashish C Bhatia, MD, FAAD  Assistant Professor of Clinical Dermatology, Department of Dermatology, Northwestern University, Feinberg School of Medicine; Medical Director for Dermatologic Research, Department of Clinical Research, DuPage Medical Group; Co-Director of Dermatologic, Laser and Cosmetic Surgery, The Dermatology Institute of DuPage Medical Group

Ashish C Bhatia, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, American Medical Association, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, and Connective Tissue Oncology Society

Disclosure: Nothing to disclose.

Coauthor(s)

Mark A Crowe, MD  Assistant Clinical Instructor, Department of Medicine, Division of Dermatology, University of Washington School of Medicine

Mark A Crowe, MD is a member of the following medical societies: American Academy of Dermatology and North American Clinical Dermatologic Society

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Carissa N Beatty, MPH Program Manager, Tobacco Technical Assistance Consortium

Carissa N Beatty, MPH is a member of the following medical societies: American Public Health Association

Disclosure: Nothing to disclose.

Ashish C Bhatia, MD, FAAD Assistant Professor, Department of Dermatology, Northwestern University, Feinberg School of Medicine; Director of Clinical Research, Department of Dermatology and Dermatologic Surgery; Director of Dermatologic Surgery and Dermatology, The Dermatology Institute of DuPage Medical Group

Ashish C Bhatia, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, American Medical Association, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, and Connective Tissue Oncology Society

Disclosure: Nothing to disclose.

David F Butler, MD Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Tracy Campbell, MD Staff Physician, Department of Dermatology, Rush Medical Center

Tracy Campbell, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Chicago Dermatological Society, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

Edward F Chan, MD Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Edward F Chan, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Mark W Cobb, MD Consulting Staff, WNC Dermatological Associates

Mark W Cobb, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and American Society of Dermatopathology

Disclosure: Nothing to disclose.

Kevin P Connelly, DO Clinical Assistant Professor, Department of Pediatrics, Division of General Pediatrics and Emergency Care, Virginia Commonwealth University; Medical Director, Paws for Health Pet Visitation Program of the Richmond SPCA; Pediatric Emergency Physician, Emergency Consultants Inc, Chippenham Medical Center

Kevin P Connelly, DO is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Seth Forman, MD Private Practice, Tampa, Florida

Seth Forman, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Abbott Laboratories Honoraria Speaking and teaching

Catharine Lisa Kauffman, MD, FACP Georgetown Dermatology and Georgetown Dermpath

Catharine Lisa Kauffman, MD, FACP is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Royal Society of Medicine, Society for Investigative Dermatology, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

John W King, MD Professor of Medicine, Chief, Section of Infectious Diseases, Director, Viral Therapeutics Clinics for Hepatitis, Louisiana State University Health Sciences Center; Consultant in Infectious Diseases, Overton Brooks Veterans Affairs Medical Center

John W King, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Association of Subspecialty Professors, Infectious Diseases Society of America, and Sigma Xi

Disclosure: emedicine $50.00 author of chapter; MERCK None Other

Daniel R Lucey, MD, MPH Chief, Fellowship Program Director, Department of Internal Medicine, Division of Infectious Diseases, Washington Hospital Center; Professor, Department of Internal Medicine, Uniformed Services University of the Health Sciences

Daniel R Lucey, MD, MPH is a member of the following medical societies: Alpha Omega Alpha and American College of Physicians

Disclosure: Nothing to disclose.

Julia R Nunley, MD Professor, Program Director, Dermatology Residency, Department of Dermatology, Virginia Commonwealth University Medical Center

Julia R Nunley, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Nephrology, International Society of Nephrology, Medical Dermatology Society, Medical Society of Virginia, National Kidney Foundation, Phi Beta Kappa, and Women's Dermatologic Society

Disclosure: Novartis Grant/research funds Consulting; Biolex Grant/research funds sub-investigator

Robert Orenstein, DO Associate Professor, Department of Medicine, Medical College of Virginia, Virginia Commonwealth University; Medical Director, Infectious Disease Clinic, Medical College of Virginia Hospitals

Robert Orenstein, DO is a member of the following medical societies: Infectious Diseases Society of America

Disclosure: Nothing to disclose.

David Rowe, MD Pathologist, Laboratory Medicine, Martha Jefferson Hospital

David Rowe, MD is a member of the following medical societies: United States and Canadian Academy of Pathology

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

Sung W Yoon, MD, Fellow, Department of Plastic Surgery, Mayo Clinic at Scottsdale

Disclosure: Nothing to disclose.

Additional Contributors

Carissa N Beatty, MPH Program Manager, Tobacco Technical Assistance Consortium

Carissa N Beatty, MPH is a member of the following medical societies: American Public Health Association

Disclosure: Nothing to disclose.

Ashish C Bhatia, MD, FAAD Assistant Professor, Department of Dermatology, Northwestern University, Feinberg School of Medicine; Director of Clinical Research, Department of Dermatology and Dermatologic Surgery; Director of Dermatologic Surgery and Dermatology, The Dermatology Institute of DuPage Medical Group

Ashish C Bhatia, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, American Medical Association, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, and Connective Tissue Oncology Society

Disclosure: Nothing to disclose.

David F Butler, MD Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Tracy Campbell, MD Staff Physician, Department of Dermatology, Rush Medical Center

Tracy Campbell, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Chicago Dermatological Society, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

Edward F Chan, MD Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Edward F Chan, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Mark W Cobb, MD Consulting Staff, WNC Dermatological Associates

Mark W Cobb, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and American Society of Dermatopathology

Disclosure: Nothing to disclose.

Kevin P Connelly, DO Clinical Assistant Professor, Department of Pediatrics, Division of General Pediatrics and Emergency Care, Virginia Commonwealth University; Medical Director, Paws for Health Pet Visitation Program of the Richmond SPCA; Pediatric Emergency Physician, Emergency Consultants Inc, Chippenham Medical Center

Kevin P Connelly, DO is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Seth Forman, MD Private Practice, Tampa, Florida

Seth Forman, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Abbott Laboratories Honoraria Speaking and teaching

Catharine Lisa Kauffman, MD, FACP Georgetown Dermatology and Georgetown Dermpath

Catharine Lisa Kauffman, MD, FACP is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Royal Society of Medicine, Society for Investigative Dermatology, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

John W King, MD Professor of Medicine, Chief, Section of Infectious Diseases, Director, Viral Therapeutics Clinics for Hepatitis, Louisiana State University Health Sciences Center; Consultant in Infectious Diseases, Overton Brooks Veterans Affairs Medical Center

John W King, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Association of Subspecialty Professors, Infectious Diseases Society of America, and Sigma Xi

Disclosure: emedicine $50.00 author of chapter; MERCK None Other

Daniel R Lucey, MD, MPH Chief, Fellowship Program Director, Department of Internal Medicine, Division of Infectious Diseases, Washington Hospital Center; Professor, Department of Internal Medicine, Uniformed Services University of the Health Sciences

Daniel R Lucey, MD, MPH is a member of the following medical societies: Alpha Omega Alpha and American College of Physicians

Disclosure: Nothing to disclose.

Julia R Nunley, MD Professor, Program Director, Dermatology Residency, Department of Dermatology, Virginia Commonwealth University Medical Center

Julia R Nunley, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Nephrology, International Society of Nephrology, Medical Dermatology Society, Medical Society of Virginia, National Kidney Foundation, Phi Beta Kappa, and Women's Dermatologic Society

Disclosure: Novartis Grant/research funds Consulting; Biolex Grant/research funds sub-investigator

Robert Orenstein, DO Associate Professor, Department of Medicine, Medical College of Virginia, Virginia Commonwealth University; Medical Director, Infectious Disease Clinic, Medical College of Virginia Hospitals

Robert Orenstein, DO is a member of the following medical societies: Infectious Diseases Society of America

Disclosure: Nothing to disclose.

David Rowe, MD Pathologist, Laboratory Medicine, Martha Jefferson Hospital

David Rowe, MD is a member of the following medical societies: United States and Canadian Academy of Pathology

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

Sung W Yoon, MD, Fellow, Department of Plastic Surgery, Mayo Clinic at Scottsdale

Disclosure: Nothing to disclose.

References
  1. Scholz J, Rosen-Wolff A, Bugert J, et al. Epidemiology of molluscum contagiosum using genetic analysis of the viral DNA. J Med Virol. Feb 1989;27(2):87-90. [Medline].

  2. Freeman CL, Moriarty AT. Molluscum contagiosum presenting as cellulitis in an AIDS patient: cytologic and ultrastructural features. Diagn Cytopathol. Jun 1995;12(4):345-9. [Medline].

  3. Choong KY, Roberts LJ. Molluscum contagiosum, swimming and bathing: a clinical analysis. Australas J Dermatol. May 1999;40(2):89-92. [Medline].

  4. Connell CO, Oranje A, Van Gysel D, Silverberg NB. Congenital molluscum contagiosum: report of four cases and review of the literature. Pediatr Dermatol. Sep-Oct 2008;25(5):553-6. [Medline].

  5. Ahn BK, Kim BD, Lee SJ, Lee SH. Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment. J Am Acad Dermatol. Mar 2005;52(3 Pt 1):532-3. [Medline].

  6. Fery-Blanco C, Pelletier F, Humbert P, Aubin F. [Disseminated molluscum contagiosum during topical treatment of atopic dermatitis with tacrolimus: efficacy of cidofovir]. Ann Dermatol Venereol. May 2007;134(5 Pt 1):457-9. [Medline].

  7. Wilson LM, Reid CM. Molluscum contagiosum in atopic dermatitis treated with 0.1% tacrolimus ointment. Australas J Dermatol. Aug 2004;45(3):184-5. [Medline].

  8. Senkevich TG, Koonin EV, Bugert JJ, et al. The genome of molluscum contagiosum virus: analysis and comparison with other poxviruses. Virology. Jun 23 1997;233(1):19-42. [Medline].

  9. Mahe A, Prual A, Konate M, Bobin P. Skin diseases of children in Mali: a public health problem. Trans R Soc Trop Med Hyg. Sep-Oct 1995;89(5):467-70. [Medline].

  10. Konya J, Thompson CH. Molluscum contagiosum virus: antibody responses in persons with clinical lesions and seroepidemiology in a representative Australian population. J Infect Dis. Mar 1999;179(3):701-4. [Medline].

  11. Becker TM, Blount JH, Douglas J, Judson FN. Trends in molluscum contagiosum in the United States, 1966-1983. Sex Transm Dis. Apr-Jun 1986;13(2):88-92. [Medline].

  12. Reynolds MG, Holman RC, Yorita Christensen KL, Cheek JE, Damon IK. The Incidence of Molluscum contagiosum among American Indians and Alaska Natives. PLoS One. 2009;4(4):e5255. [Medline]. [Full Text].

  13. Laxmisha C, Thappa DM, Jaisankar TJ. Clinical profile of molluscum contagiosum in children versus adults. Dermatol Online J. Dec 2003;9(5):1. [Medline]. [Full Text].

  14. Dohil MA, Lin P, Lee J, Lucky AW, Paller AS, Eichenfield LF. The epidemiology of molluscum contagiosum in children. J Am Acad Dermatol. Jan 2006;54(1):47-54. [Medline].

  15. Smolinski KN, Yan AC. How and when to treat molluscum contagiosum and warts in children. Pediatr Ann. Mar 2005;34(3):211-21. [Medline].

  16. [Guideline] Clinical Effectiveness Group. National guideline for the management of molluscum contagiosum. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect. Aug 1999;75 Suppl 1:S80-1. [Medline].

  17. Braue A, Ross G, Varigos G, Kelly H. Epidemiology and impact of childhood molluscum contagiosum: a case series and critical review of the literature. Pediatr Dermatol. Jul-Aug 2005;22(4):287-94. [Medline].

  18. Mansur AT, Göktay F, Gündüz S, Serdar ZA. Multiple giant molluscum contagiosum in a renal transplant recipient. Transpl Infect Dis. Sep 2004;6(3):120-3. [Medline].

  19. Betlloch I, Pinazo I, Mestre F, et al. Molluscum contagiosum in human immunodeficiency virus infection: response to zidovudine. Int J Dermatol. Jun 1989;28(5):351-2. [Medline].

  20. Hornor G. Ano-genital warts in children: Sexual abuse or not?. J Pediatr Health Care. Jul-Aug 2004;18(4):165-70. [Medline].

  21. Nageswaran A, Kinghorn GR. Sexually transmitted diseases in children: herpes simplex virus infection, cytomegalovirus infection, hepatitis B virus infection and molluscum contagiosum. Genitourin Med. Aug 1993;69(4):303-11. [Medline].

  22. Munoz-Perez MA, Colmenero MA, Rodriguez-Pichardo A, et al. Disseminated cryptococcosis presenting as molluscum-like lesions as the first manifestation of AIDS. Int J Dermatol. Sep 1996;35(9):646-8. [Medline].

  23. Buller RM, Burnett J, Chen W, Kreider J. Replication of molluscum contagiosum virus. Virology. Nov 10 1995;213(2):655-9. [Medline].

  24. Cribier B, Scrivener Y, Grosshans E. Molluscum contagiosum: histologic patterns and associated lesions. A study of 578 cases. Am J Dermatopathol. Apr 2001;23(2):99-103. [Medline].

  25. Hanna D, Hatami A, Powell J, et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatr Dermatol. Nov-Dec 2006;23(6):574-9. [Medline].

  26. Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch Dermatol. Oct 1999;135(10):1167-9. [Medline].

  27. Theos AU, Cummins R, Silverberg NB, Paller AS. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis. Aug 2004;74(2):134-8, 141-2. [Medline].

  28. Ross GL, Orchard DC. Combination topical treatment of molluscum contagiosum with cantharidin and imiquimod 5% in children: a case series of 16 patients. Australas J Dermatol. May 2004;45(2):100-2. [Medline].

  29. Syed TA, Lundin S, Ahmad M. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of molluscum contagiosum in males. A placebo-controlled, double-blind study. Dermatology. 1994;189(1):65-8. [Medline].

  30. Watanabe T, Tamaki K. Cidofovir diphosphate inhibits molluscum contagiosum virus DNA polymerase activity. J Invest Dermatol. May 2008;128(5):1327-9. [Medline].

  31. Ordoukhanian E, Lane AT. Warts and molluscum contagiosum: beware of treatments worse than the disease. Postgrad Med. Feb 1997;101(2):223-6, 229-32, 235. [Medline].

  32. Takematsu H, Tagami H. Proinflammatory properties of molluscum bodies. Arch Dermatol Res. 1994;287(1):102-6. [Medline].

  33. Romiti R, Ribeiro AP, Grinblat BM, et al. Treatment of molluscum contagiosum with potassium hydroxide: a clinical approach in 35 children. Pediatr Dermatol. May-Jun 1999;16(3):228-31. [Medline].

  34. Romiti R, Ribeiro AP, Romiti N. Evaluation of the effectiveness of 5% potassium hydroxide for the treatment of molluscum contagiosum. Pediatr Dermatol. Nov-Dec 2000;17(6):495. [Medline].

  35. Mathes EF, Frieden IJ. Treatment of molluscum contagiosum with cantharidin: a practical approach. Pediatr Ann. Mar 2010;39(3):124-8, 130. [Medline].

  36. Niizeki K, Hashimoto K. Treatment of molluscum contagiosum with silver nitrate paste. Pediatr Dermatol. Sep-Oct 1999;16(5):395-7. [Medline].

  37. Silverberg NB, Sidbury R, Mancini AJ. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. J Am Acad Dermatol. Sep 2000;43(3):503-7. [Medline].

  38. Cathcart S, Coloe J, Morrell DS. Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection. Clin Pediatr (Phila). Mar 2009;48(2):161-5. [Medline].

  39. Epstein E. Cantharidin treatment of molluscum contagiosum. Acta Derm Venereol. 1989;69(1):91-2. [Medline].

  40. Martin-Garcia RF, Garcia ME, Rosado A. Modified curettage technique for molluscum contagiosum. Pediatr Dermatol. Mar-Apr 2007;24(2):192-4. [Medline].

  41. Simonart T, De Maertelaer V. Curettage treatment for molluscum contagiosum: a follow-up survey study. Br J Dermatol. Nov 2008;159(5):1144-7. [Medline].

  42. Squeezing causes less scarring than phenol ablation in molluscum contagiosum. BMJ. Dec 11 1999;319(7224):E. [Medline].

  43. Weller R, O'Callaghan CJ, MacSween RM, White MI. Scarring in Molluscum contagiosum: comparison of physical expression and phenol ablation. BMJ. Dec 11 1999;319(7224):1540. [Medline].

  44. Lindau MS, Munar MY. Use of duct tape occlusion in the treatment of recurrent molluscum contagiosum. Pediatr Dermatol. Sep-Oct 2004;21(5):609. [Medline].

  45. Binder B, Weger W, Komericki P, Kopera D. Treatment of molluscum contagiosum with a pulsed dye laser: Pilot study with 19 children. J Dtsch Dermatol Ges. Feb 2008;6(2):121-5. [Medline].

  46. Chatproedprai S, Suwannakarn K, Wananukul S, Theamboonlers A, Poovorawan Y. Efficacy of pulsed dyed laser (585 nm) in the treatment of molluscum contagiosum subtype 1. Southeast Asian J Trop Med Public Health. Sep 2007;38(5):849-54. [Medline].

  47. Hammes S, Greve B, Raulin C. [Molluscum contagiosum: treatment with pulsed dye laser]. Hautarzt. Jan 2001;52(1):38-42. [Medline].

  48. Hughes PS. Treatment of molluscum contagiosum with the 585-nm pulsed dye laser. Dermatol Surg. Feb 1998;24(2):229-30. [Medline].

  49. Michel JL. Treatment of molluscum contagiosum with 585 nm collagen remodeling pulsed dye laser. Eur J Dermatol. Mar-Apr 2004;14(2):103-6. [Medline].

  50. Nelson MR, Chard S, Barton SE. Intralesional interferon for the treatment of recalcitrant molluscum contagiosum in HIV antibody positive individuals--a preliminary report. Int J STD AIDS. Sep-Oct 1995;6(5):351-2. [Medline].

  51. Inui S, Asada H, Yoshikawa K. Successful treatment of molluscum contagiosum in the immunosuppressed adult with topical injection of streptococcal preparation OK-432. J Dermatol. Sep 1996;23(9):628-30. [Medline].

  52. Metkar A, Pande S, Khopkar U. An open, nonrandomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Indian J Dermatol Venereol Leprol. Nov-Dec 2008;74(6):614-8. [Medline].

  53. Skinner RB Jr, Ray S, Talanin NY. Treatment of molluscum contagiosum with topical 5% imiquimod cream. Pediatr Dermatol. Sep-Oct 2000;17(5):420. [Medline].

  54. Barba AR, Kapoor S, Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatol Online J. Feb 2001;7(1):20. [Medline].

  55. Hengge UR, Esser S, Schultewolter T. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol. Nov 2000;143(5):1026-31. [Medline].

  56. Maronn M, Salm C, Lyon V, Galbraith S. One-year experience with candida antigen immunotherapy for warts and molluscum. Pediatr Dermatol. Mar-Apr 2008;25(2):189-92. [Medline].

  57. Lacarrubba F, Nasca MR, Micali G. Advances in the use of topical imiquimod to treat dermatologic disorders. Ther Clin Risk Manag. Feb 2008;4(1):87-97. [Medline]. [Full Text].

  58. Myhre PE, Levy ML, Eichenfield LF, Kolb VB, Fielder SL, Meng TC. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children. Pediatr Dermatol. Jan-Feb 2008;25(1):88-95. [Medline].

  59. Bayerl C, Feller G, Goerdt S. Experience in treating molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol. Nov 2003;149 Suppl 66:25-9. [Medline].

  60. Brown CW Jr, O'Donoghue M, Moore J, Tharp M. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod. Cutis. Jun 2000;65(6):363-6. [Medline].

  61. Veregen (sinecatechins) Ointment, 15% [package insert]. Planegg/Martinsried, Germany: MediGene AG; 2011.

  62. Toro JR, Wood LV, Patel NK. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol. Aug 2000;136(8):983-5. [Medline].

  63. Zabawski EJ Jr, Cockerell CJ. Topical cidofovir for molluscum contagiosum in children. Pediatr Dermatol. Sep-Oct 1999;16(5):414-5. [Medline].

  64. [Best Evidence] van der Wouden JC, van der Sande R, van Suijlekom-Smit LW, Berger M, Butler C, Koning S. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. Oct 7 2009;CD004767. [Medline].

  65. Burke BE, Baillie JE, Olson RD. Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomed Pharmacother. May 2004;58(4):245-7. [Medline].

Previous
Next
 
Note the central umbilication in these classic lesions of molluscum contagiosum.
Approximately 10% of patients develop eczema around lesions. Eczema associated with molluscum lesions spontaneously subsides following removal.
Molluscum contagiosum on the shaft of the penis. Molluscum contagiosum in the genital region of adults is most commonly acquired as a sexually transmitted disease.
Larger lesions may have several clumps of molluscum bodies rather than the more common single central umbilication. This may make them difficult to recognize as molluscum contagiosum.
Molluscum lesions may become quite numerous in intertriginous areas. This child has autoinoculated lesions to both inner thighs.
After trauma, or spontaneously after several months, inflammatory changes result in suppuration, crusting and eventual resolution of the lesion. This inflammatory stage does not usually represent secondary infection and seldom requires antibiotic therapy.
Lesions of molluscum contagiosum have a characteristic histopathology. Lobules containing hyalinized molluscum bodies, also known as Henderson-Paterson bodies, are diagnostic.
This lesion of cutaneous coccidioidomycosis could be included among the differential diagnoses of molluscum contagiosum.
This keratoacanthoma could be included among the differential diagnoses of molluscum contagiosum.
Lesions on the upper eyelid of a 3-year-old child.
In a patient who had preexisting molluscum contagiosum, the virus was inoculated along a line of minor skin trauma, resulting in the development of the 3 new lesions.
Molluscum contagiosum on the right axilla.
Presented here are the classic umbilicated papules of molluscum contagiosum lesions on the cheek of a child. Facial lesions occur frequently in children, although lesions generally are few.
Molluscum contagiosum rarely occurs on the face in an adult unless the patient is infected with HIV. When molluscum contagiosum occurs in individuals infected with HIV, facial lesions are common and frequently numerous.
Molluscum contagiosum lesions in individuals infected with HIV may number in the hundreds. In addition, they may become quite large and prominent.
This low-power view of a molluscum contagiosum lesion shows the classic cup-shaped invagination of the epidermis into dermis. The Henderson-Paterson bodies are identified readily and stained purple to red in this image.
This is a medium-power view of a molluscum contagiosum lesion. Magnification allows better demonstration of the intracytoplasmic molluscum bodies (staining purple-pink) within the keratinocytes.
This molluscum contagiosum body is an intracytoplasmic inclusion body. Notice in the image that the keratinocyte nuclei are displaced to the periphery of the cell and that the intracytoplasmic inclusions have a granular quality.
Multiple papules on the face of a man with HIV.
Cytoplasmic viral inclusions become progressively larger toward the epidermal surface (hematoxylin and eosin, 200X)
Low-power histopathologic examination reveals an overall cup-shaped appearance.
Viral particles have a dumbbell-shaped appearance. Courtesy of Alvin Zelickson, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.